Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Smoldering Multiple Myeloma 3Pancreatic Neoplasms 2Multiple Myeloma 2Melanoma 2Glioma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Arthritis, Rheumatoid 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Multiple Endocrine Neoplasia 1Lung Neoplasms 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Breast Diseases 1Astrocytoma 1Acute Graft Versus Host Disease 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Leflunomide × Clear all
NCT01611675 2017-04-06

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Massachusetts General Hospital

Phase 1 Terminated
3 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡